Previous 10 | Next 10 |
Shares of Fate Therapeutics (NASDAQ: FATE) dropped nearly 24% last month, according to data provided by S&P Global Market Intelligence . That was almost twice the fall of the S&P 500 , which declined 12.5% in March due to the abrupt uncertainty ushered in by the coronavirus pandemi...
Individual investors might be tempted to chase vaccines for SARS-CoV-2 or treatments for COVID-19, but it's still way too early to know which companies will succeed in their efforts. There will likely (hopefully) be multiple vaccines and treatments approved for use in the next two years, and est...
The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...
On Thursday after the closing bell, Fate Therapeutics (NASDAQ: FATE) announced that it had gotten the backing of Johnson & Johnson 's (NYSE: JNJ) Janssen Biotech division in a drug development deal that could be worth more than $3 billion ... if everything goes perfectly. News of the...
Shares of Fate Therapeutics (NASDAQ: FATE) gained over 18% today after the company announced an equity investment from and a partnership with Johnson & Johnson subsidiary Janssen. The pair will leverage their respective technology platforms in cellular medicine to develop immunotherapy...
Capricor Therapeutics (NASDAQ: CAPR ) +26% on providing its CAP-1002 cell therapy under compassionate use for patients with advanced COVID-19. More news on: Capricor Therapeutics, Inc., Fate Therapeutics, Inc., SAExploration Holdings, Inc., Stocks on the move, Read m...
Fate Therapeutics (NASDAQ: FATE ) inks a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech aimed at developing cell therapies for cancer. More news on: Fate Therapeutics, Inc., Johnson & Johnson, Healthcare stocks news, Stocks on t...
ꟷ Collaboration leverages Company’s iPSC product platform and Janssen’s proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates ꟷ ꟷ Fate to receive $50 million upfront payment and $50 million equity invest...
SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that the first patient has been treated in th...
Introduction Since my last article on Allogene Therapeutics ( ALLO ) about 5 months ago, its share price has fallen by around 30%, largely in part due to the stock market crash driven by the COVID-19 global pandemic . Despite the progress in clinical development, strong management tea...
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
2024-06-17 07:30:04 ET Piper Sandler analyst issues OVERWEIGHT recommendation for FATE on June 17, 2024 06:03AM ET. The previous analyst recommendation was Neutral. FATE was trading at $3.61 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellula...